CAR-DC cell therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called CAR-DC, which uses your immune cells to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have an advanced solid tumor (like lung, liver, colorectal, or stomach cancer) that has spread or is locally advanced.
- Your tumor tests positive for one of these markers: EphA2, Claudin18.2, TROP2, HER2, GCC, GPC-3, or CEA, with a strong level of expression (2+ or higher).
- Standard treatments have failed, or you cannot or do not want to take them.
- You are generally able to care for yourself (ECOG score 0-2) and have a life expectancy of more than 3 months.
- Your major organs (bone marrow, kidneys, liver, heart) must be working well enough, and you must not have certain infections or conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a special type of cell therapy called CAR T cells. The cells are changed in the lab to find and attack a protein called CD276 on the surface of solid tumors. If the treatment works, your own immune cells could shrink the tumor or slow its growth.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.